【摘要】 目的探讨索拉非尼(Sorafenib)联合热疗(hyperthermia)不同联合方案对肝癌HepG-2细胞增殖抑制的影响。方法索拉非尼及热疗单独、同时、序贯联合后以MTT法测定HepG-2细胞增殖。结果索拉非尼和热疗均对肝癌HepG-2细胞增殖抑制作用(P<0.01),同时应用具有协同作用(P<0.01);索拉非尼先用组与热疗先用组相比疗效相似(P>0.05),同时联合组高于序贯联合组(P<0.01),联合组及序贯用药组均优于索拉非尼及热疗单用组。联合组均高于单独应用组(P<0.01)。结论索拉非尼和热疗对肝癌HepG-2细胞均有增殖抑制作用,索拉非尼联合热疗具有协同作用。更多还原

【Abstract】 Objective To observe the inhibitory effect on the Proliferation of HepG-2 cells by the treatment of sorafenib combined with hyperthermia.Methods The Proliferation of HepG-2 cells was determined by MTT assy after administration with sorafenib alone,hyperthermia alone or sorafenib in combination with hyperthermia.Results Either sorafenib or hyperthermia had an inhibitory effect on HepG-2 cells and sorafenib combined with hyperthermia revealed a synergistic effect(P<0.01).The efficacy in patients receiving sequential chemotherapy with sorafenib was similar to that in patients receiving sequential chemotherapy with hyperthermia(P>0.05).The inhibitory effect was higher in the dual-therapy group than in the monotherapy groups(P<0.01).The inhibitory effect was higher in sorafenib combined with hyperthermia than the sequential chemotherapy(P<0.01).Conclusions Sorafenib or hyperthermia alone has an inhibitory effect on the proliferation of HepG-2 cells.Simultaneous administration with sorafenib and hyperthermia has a synergistic effect.Sequential chemotherapy is higher than the sorafenib or hyperthermia alone.更多还原